Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 01 May 2016 Status changed from recruiting to completed.
- 21 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.